| 臺大學術典藏 |
2021-09-04T06:11:17Z |
Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection
|
Yang S.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:08Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; JIA-HORNG KAO; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2021-09-04T05:17:00Z |
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study
|
Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:46Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:44Z |
Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction?
|
Hsu S.-J.; Yang S.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:42Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; Liu C.-J.; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:37Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:27Z |
High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy
|
Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:25Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:17Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:16Z |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; Liu C.-J.; Dai C.-Y.; JIA-HORNG KAO; Chuang W.-L.; Lin H.-C.; Yu M.-L. |
| 臺大學術典藏 |
2021-09-01T02:02:15Z |
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma
|
Chen L.-T.; Lin J.-T.; Tai J.J.; Chen G.-H.; Yeh H.-Z.; Yang S.-S.; Wang H.-P.; Kuo S.-H.; Sheu B.-S.; Jan C.-M.; Wang W.-M.; Wang T.-E.; Wu C.-W.; Chen C.-L.; Su I.-J.; Whang-Peng J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2021-07-03T03:35:14Z |
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study
|
Liu C.-J.; Lai M.-Y.; Chao Y.-C.; Liao L.-Y.; Yang S.-S.; Hsiao T.-J.; Hsieh T.-Y.; Lin C.-L.; Hu J.-T.; Chen C.-L.; PEI-JER CHEN; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:34:58Z |
Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial
|
Liu C.-H.; Liu C.-J.; Lin C.-.; Liang C.-C.; Hsu S.-J.; Yang S.-S.; Hsu C.-S.; Tseng T.-C.; Wang C.-C.; Lai M.-Y.; Chen J.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:57Z |
Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus
|
Huang Y.-W.; Hu C.-Y.; Chen C.-L.; Liao Y.-T.; Liu C.-J.; Lai M.-Y.; PEI-JER CHEN; Yang S.-S.; Hu J.-T.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:53Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-07-03T03:34:47Z |
Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan
|
Huang Y.-W.; Liao Y.-T.; Chen W.; Chen C.-L.; Hu J.-T.; Liu C.-J.; Lai M.-Y.; PEI-JER CHEN; Chen D.-S.; Yang S.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:42Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; PEI-JER CHEN; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:34:38Z |
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy
|
Tseng T.-C.; Yu M.-L.; Liu C.-J.; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; Liu C.-H.; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:28Z |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Lin J.-W.; Chen J.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:27Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:23Z |
Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy
|
Huang Y.-W.; Lin S.-C.; Wei S.-C.; Hu J.-T.; Chang H.-Y.; Huang S.-H.; Chen D.-S.; PEI-JER CHEN; Hsu P.-N.; Yang S.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:20Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2021-07-03T03:34:14Z |
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial
|
Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Chen S.-I.; Lin J.-W.; Yang S.-S.; Su T.-H.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:09Z |
Reduced toll-like receptor 9 expression on peripheral C D14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy
|
Huang Y.-W.; Hsu C.-K.; Lin S.-C.; Wei S.-C.; Hu J.-T.; Chang H.-Y.; Liang C.-W.; Chen D.-S.; PEI-JER CHEN; Hsu P.-N.; Yang S.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:06Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-07-03T03:33:59Z |
Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial
|
Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L. |
| 臺大學術典藏 |
2021-07-03T03:33:58Z |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial
|
Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:56Z |
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na?ve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial
|
Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L. |
| 臺大學術典藏 |
2021-07-03T03:33:36Z |
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study
|
Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:31Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.;Shih Y.-L.;Yang S.-S.;Lin C.-L.;Fang Y.-J.;Cheng P.-N.;Chen C.-Y.;Peng C.-Y.;Hsieh T.-Y.;Chiu Y.-C.;Su T.-H.;Liu C.-J.;Yang H.-C.;Pei-Jer Chen;Chen D.-S.;Kao J.-H.; Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:26Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; Su T.-H.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:21Z |
High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy
|
Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:20Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-06-25T08:10:14Z |
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study
|
Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-06-15T03:12:12Z |
Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy
|
Huang Y.-W.; Lin S.-C.; SHU-CHEN WEI; Hu J.-T.; Chang H.-Y.; Huang S.-H.; Chen D.-S.; Chen P.-J.; Hsu P.-N.; Yang S.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-06-15T03:12:11Z |
Reduced toll-like receptor 9 expression on peripheral C D14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy
|
Huang Y.-W.; Hsu C.-K.; Lin S.-C.; SHU-CHEN WEI; Hu J.-T.; Chang H.-Y.; Liang C.-W.; Chen D.-S.; Chen P.-J.; Hsu P.-N.; Yang S.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:53Z |
Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial
|
CHEN-HUA LIU; Liu C.-J.; Lin C.-.; Liang C.-C.; Hsu S.-J.; Yang S.-S.; Hsu C.-S.; Tseng T.-C.; Wang C.-C.; Lai M.-Y.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:50Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; CHEN-HUA LIU; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-05-24T07:20:49Z |
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy
|
Tseng T.-C.; Yu M.-L.; Liu C.-J.; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; CHEN-HUA LIU; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:46Z |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
|
CHEN-HUA LIU; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:46Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
CHEN-HUA LIU; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:44Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; CHEN-HUA LIU; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2021-05-24T07:20:40Z |
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial
|
CHEN-HUA LIU; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Chen S.-I.; Lin J.-W.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:34Z |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial
|
CHEN-HUA LIU; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:34Z |
Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial
|
CHEN-HUA LIU; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L. |
| 臺大學術典藏 |
2021-05-24T07:20:33Z |
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial
|
CHEN-HUA LIU; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L. |
| 臺大學術典藏 |
2021-05-24T07:20:26Z |
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study
|
CHEN-HUA LIU; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:21Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
CHEN-HUA LIU; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
